Reports
Global Interleukin Inhibitors Market: By Type: L-17, IL-23, IL-1, IL-5, IL-6, Others; By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Others; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Interleukin Inhibitors Market Outlook
The global interleukin inhibitors market is expected to grow over the forecast period 2023-2028, growing at a CAGR of 13.5%. The interleukin inhibitors market is driven by the highly effective work of interleukin inhibitors in treating autoimmune disease.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Properties and Applications
Interleukin inhibitors are referred to as the immunosuppressive agents, which limit the activity of interleukins. Interleukin is a group of cytokines that are synthesized by lymphocytes, macrophages, monocytes, and certain other cells. Their role is to regulate the immune system.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The interleukin inhibitors market is segmented based on types and applications.
Based on type, the interleukin inhibitors market is divided into:
- L-17
- IL-23
- IL-1
- IL-5
- IL-6
- Others
Based on application, the interleukin inhibitors market is segmented into:
- Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Asthma
- Inflammatory Bowel Disease
- Others
The EMR report looks into the regional interleukin inhibitors markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The global interleukin inhibitors market is being driven by the highly effective work of interleukin inhibitors in treating autoimmune disease. The interleukin inhibitors market is aided by the numerous approved interleukin inhibitor molecules for treating autoimmune conditions like rheumatoid arthritis, psoriasis, and Crohn’s disease. Moreover, R&D is in progress over interleukin inhibitor molecules, and clinical trials for late-stage molecules is expected to impact market growth positively. Higher patient adherence to these drugs due to their higher affinity and specificity, as compared to other conventional approved autoimmune therapeutics, is predicted to increase their sales.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global interleukin inhibitors market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Novartis AG
- AbbVie Inc [NYSE: ABBV]
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Johnson & Johnson Services, Inc
- F. Hoffmann-La Roche Ltd
- AstraZeneca
- Bausch Health
- GlaxoSmithKline plc
- Teva Pharmaceuticals Industries, Ltd.
- Others
The EMR report gives an in-depth insight into the interleukin inhibitors market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Application, Region |
| Breakup by Type | L-17, IL-23, IL-1, IL-5, IL-6, Others |
| Breakup by Application | Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Novartis AG [NOVN (SWX)], AbbVie Inc [ABBV (NYSE)], Eli Lilly and Company [LLY (NYSE)], Regeneron Pharmaceuticals, Inc. [REGN (NASDAQ)], Johnson & Johnson Services, Inc, F. Hoffmann-La Roche Ltd [ROG (SWX)], AstraZeneca [AZN (LON)], Bausch Health [BHC (TSE)], GlaxoSmithKline plc [GSK (LON)], Teva Pharmaceuticals Industries, Ltd. [TEVA (TLV)], Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Interleukin Inhibitors Market Analysis
8.1 Key Industry Highlights
8.2 Global Interleukin Inhibitors Historical Market (2018-2022)
8.3 Global Interleukin Inhibitors Market Forecast (2023-2028)
8.4 Global Interleukin Inhibitors Market by Type
8.4.1 L-17
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 IL-23
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 IL-1
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.4.4 IL-5
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2018-2022)
8.4.4.3 Forecast Trend (2023-2028)
8.4.5 IL-6
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2018-2022)
8.4.5.3 Forecast Trend (2023-2028)
8.4.6 Others
8.5 Global Interleukin Inhibitors Market by Application
8.5.1 Psoriasis
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Psoriatic Arthritis
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Rheumatoid Arthritis
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
8.5.4 Asthma
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2022)
8.5.4.3 Forecast Trend (2023-2028)
8.5.5 Inflammatory Bowel Disease
8.5.5.1 Market Share
8.5.5.2 Historical Trend (2018-2022)
8.5.5.3 Forecast Trend (2023-2028)
8.5.6 Others
8.6 Global Interleukin Inhibitors Market by Region
8.6.1 North America
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Europe
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Asia Pacific
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2022)
8.6.3.3 Forecast Trend (2023-2028)
8.6.4 Latin America
8.6.4.1 Market Share
8.6.4.2 Historical Trend (2018-2022)
8.6.4.3 Forecast Trend (2023-2028)
8.6.5 Middle East and Africa
8.6.5.1 Market Share
8.6.5.2 Historical Trend (2018-2022)
8.6.5.3 Forecast Trend (2023-2028)
9 North America Interleukin Inhibitors Market Analysis
9.1 United States of America
9.1.1 Market Share
9.1.2 Historical Trend (2018-2022)
9.1.3 Forecast Trend (2023-2028)
9.2 Canada
9.2.1 Market Share
9.2.2 Historical Trend (2018-2022)
9.2.3 Forecast Trend (2023-2028)
10 Europe Interleukin Inhibitors Market Analysis
10.1 United Kingdom
10.1.1 Market Share
10.1.2 Historical Trend (2018-2022)
10.1.3 Forecast Trend (2023-2028)
10.2 Germany
10.2.1 Market Share
10.2.2 Historical Trend (2018-2022)
10.2.3 Forecast Trend (2023-2028)
10.3 France
10.3.1 Market Share
10.3.2 Historical Trend (2018-2022)
10.3.3 Forecast Trend (2023-2028)
10.4 Italy
10.4.1 Market Share
10.4.2 Historical Trend (2018-2022)
10.4.3 Forecast Trend (2023-2028)
10.5 Others
11 Asia Pacific Interleukin Inhibitors Market Analysis
11.1 China
11.1.1 Market Share
11.1.2 Historical Trend (2018-2022)
11.1.3 Forecast Trend (2023-2028)
11.2 Japan
11.2.1 Market Share
11.2.2 Historical Trend (2018-2022)
11.2.3 Forecast Trend (2023-2028)
11.3 India
11.3.1 Market Share
11.3.2 Historical Trend (2018-2022)
11.3.3 Forecast Trend (2023-2028)
11.4 ASEAN
11.4.1 Market Share
11.4.2 Historical Trend (2018-2022)
11.4.3 Forecast Trend (2023-2028)
11.5 Australia
11.5.1 Market Share
11.5.2 Historical Trend (2018-2022)
11.5.3 Forecast Trend (2023-2028)
11.6 Others
12 Latin America Interleukin Inhibitors Market Analysis
12.1 Brazil
12.1.1 Market Share
12.1.2 Historical Trend (2018-2022)
12.1.3 Forecast Trend (2023-2028)
12.2 Argentina
12.2.1 Market Share
12.2.2 Historical Trend (2018-2022)
12.2.3 Forecast Trend (2023-2028)
12.3 Mexico
12.3.1 Market Share
12.3.2 Historical Trend (2018-2022)
12.3.3 Forecast Trend (2023-2028)
12.4 Others
13 Middle East and Africa Interleukin Inhibitors Market Analysis
13.1 Saudi Arabia
13.1.1 Market Share
13.1.2 Historical Trend (2018-2022)
13.1.3 Forecast Trend (2023-2028)
13.2 United Arab Emirates
13.2.1 Market Share
13.2.2 Historical Trend (2018-2022)
13.2.3 Forecast Trend (2023-2028)
13.3 Nigeria
13.3.1 Market Share
13.3.2 Historical Trend (2018-2022)
13.3.3 Forecast Trend (2023-2028)
13.4 South Africa
13.4.1 Market Share
13.4.2 Historical Trend (2018-2022)
13.4.3 Forecast Trend (2023-2028)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 Novartis AG
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 AbbVie Inc.
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Eli Lilly and Company
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Regeneron Pharmaceuticals, Inc.
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 Johnson and Johnson Services, Inc.
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 F. Hoffmann-La Roche Ltd.
16.2.6.1 Company Overview
16.2.6.2 Product Portfolio
16.2.6.3 Demographic Reach and Achievements
16.2.6.4 Certifications
16.2.7 AstraZeneca
16.2.7.1 Company Overview
16.2.7.2 Product Portfolio
16.2.7.3 Demographic Reach and Achievements
16.2.7.4 Certifications
16.2.8 Bausch Health
16.2.8.1 Company Overview
16.2.8.2 Product Portfolio
16.2.8.3 Demographic Reach and Achievements
16.2.8.4 Certifications
16.2.9 GlaxoSmithKline plc
16.2.9.1 Company Overview
16.2.9.2 Product Portfolio
16.2.9.3 Demographic Reach and Achievements
16.2.9.4 Certifications
16.2.10 Teva Pharmaceuticals Industries, Ltd.
16.2.10.1 Company Overview
16.2.10.2 Product Portfolio
16.2.10.3 Demographic Reach and Achievements
16.2.10.4 Certifications
16.2.11 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Interleukin Inhibitors Market: Key Industry Highlights, 2018 and 2028
2. Global Interleukin Inhibitors Historical Market: Breakup by Type (USD Million), 2018-2022
3. Global Interleukin Inhibitors Market Forecast: Breakup by Type (USD Million), 2023-2028
4. Global Interleukin Inhibitors Historical Market: Breakup by Application (USD Million), 2018-2022
5. Global Interleukin Inhibitors Market Forecast: Breakup by Application (USD Million), 2023-2028
6. Global Interleukin Inhibitors Historical Market: Breakup by Region (USD Million), 2018-2022
7. Global Interleukin Inhibitors Market Forecast: Breakup by Region (USD Million), 2023-2028
8. North America Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2022
9. North America Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2023-2028
10. Europe Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2022
11. Europe Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2023-2028
12. Asia Pacific Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2022
13. Asia Pacific Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Latin America Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2022
15. Latin America Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Middle East and Africa Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2022
17. Middle East and Africa Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Global Interleukin Inhibitors Market Structure
Key Questions Answered in the Report
The global interleukin inhibitors market is projected to grow at a CAGR of 13.5% between 2023 and 2028.
The major drivers of the market include the research and development activities, rise in awareness amongst the consumers and physicians, rise in the prevalence of chronic inflammatory diseases such as psoriasis, arthritis, rise in FDA approvals for novel drugs and therapies, increase in the prevalence of autoimmune diseases, and high adoption of advanced treatment options.
The highly effective work of interleukin inhibitors in treating autoimmune diseases and higher patient adherence are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Based on type, the interleukin inhibitors market is divided into L-17, IL-23, IL-1, IL-5, and IL-6, among others.
The major applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, and inflammatory bowel disease, among others.
The major players in the industry are Novartis AG, AbbVie Inc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Johnson & Johnson Services, Inc, F. Hoffmann-La Roche Ltd, AstraZeneca, Bausch Health, GlaxoSmithKline plc, and Teva Pharmaceuticals Industries, Ltd., among others.
Analyst Review
The global interleukin inhibitors market has been driven by the highly effective work of interleukin inhibitors in treating autoimmune diseases in the historical period. Aided by the rise in awareness amongst the consumers and physicians and rise in the prevalence of chronic inflammatory diseases, the market is expected to witness further growth in the forecast period of 2023-2028, growing at a CAGR of 13.5%.
EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on type, the interleukin inhibitors market is divided into L-17, IL-23, IL-1, IL-5, and IL-6, among others. The major applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, and inflammatory bowel disease, among others. The major regional markets for the interleukin inhibitors market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The major players in the industry are Novartis AG, AbbVie Inc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Johnson & Johnson Services, Inc, F. Hoffmann-La Roche Ltd, AstraZeneca, Bausch Health, GlaxoSmithKline plc, and Teva Pharmaceuticals Industries, Ltd., among others.
EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2799-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER